Julián Alejandro Rivillas/LinkedIn
Oct 24, 2025, 12:08
Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
Julián Alejandro Rivillas, Stroke Fellow at University of Montreal Hospital Center, shared on LinkedIn:
”DAY 1: TRACE-5: Tenecteplase improved 90-day functional outcomes and early reperfusion compared with low-dose alteplase, with no safety difference — interim phase II results.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Feb 17, 2026, 16:34ISTH Names Five Global Recipients of 2026 Esteemed Career Awards
-
Feb 17, 2026, 16:16Flora Peyvandi: A Multicenter Initiative to Improve Guideline Adherence in Pediatric ITP
-
Feb 17, 2026, 16:14Hendrianus The: Intravenous Cangrelor in Hemodynamically Unstable Patients Undergoing PCI
-
Feb 17, 2026, 15:42Paul Wischmeyer: Nutrient Absorption in the GI Tract
-
Feb 17, 2026, 15:40Mahesan Subramaniam: Reversing Age-Related Decline in Blood Stem Cells
-
Feb 17, 2026, 15:38Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT
-
Feb 17, 2026, 15:34Jeff June: When Safety Warnings Outlive the Evidence – What Statins Teach Us About Stroke Prevention and Biology
-
Feb 17, 2026, 15:32Gabrielle Sarlon: Key Messages to Improve VTE Management in Women of Childbearing Age
-
Feb 17, 2026, 15:27Piezo1 Gain-of-Function Mutation Explains Thromboembolic Complications in Hereditary Xerocytosis – JTH